On this page
Ringers
Sodium Chloride, Potassium Chloride, and Calcium Chloride · Irrigant
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Calcium Chloride | .033 g/100mL | 828525 | View |
| Calcium Chloride | 33 mg/100mL | 828525 | View |
| Potassium Chloride | .03 g/100mL | 628953 | View |
| Potassium Chloride | 30 mg/100mL | 628953 | View |
| Sodium Chloride | .86 g/100mL | 707251 | View |
| Sodium Chloride | 860 mg/100mL | 707251 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Blood Coagulation Factor [EPC] | EPC | All 23 members |
| Calcium [CS] | CS | All 23 members |
| Cations | EPC | All 23 members |
| Divalent [CS] | CS | All 23 members |
| Increased Coagulation Factor Activity [PE] | PE | All 23 members |
| Increased Large Intestinal Motility [PE] | PE | All 83 members |
| Inhibition Large Intestine Fluid/Electrolyte Absorption [PE] | PE | All 83 members |
| Osmotic Activity [MoA] | MoA | All 105 members |
| Osmotic Laxative [EPC] | EPC | All 103 members |
| Phosphate Binder [EPC] | EPC | All 42 members |
| Phosphate Chelating Activity [MoA] | MoA | All 42 members |
| Potassium Compounds [CS] | CS | All 49 members |
| Potassium Salt [EPC] | EPC | All 49 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 018156-001 | RINGER'S IN PLASTIC CONTAINER | SOLUTION | CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE | Prescription | AT |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 25 | Labeling | Approved | February 13, 2004 | — |
| Supplement | 24 | Manufacturing (CMC) | Approved | August 19, 2002 | Standard |
| Supplement | 23 | Manufacturing (CMC) | Approved | April 10, 2002 | Standard |
| Supplement | 21 | Manufacturing (CMC) | Approved | May 28, 1998 | Standard |
| Supplement | 19 | Manufacturing (CMC) | Approved | September 11, 1990 | Standard |
| Supplement | 15 | Manufacturing (CMC) | Approved | March 5, 1987 | Standard |
| Supplement | 16 | Labeling | Approved | July 17, 1985 | — |
| Supplement | 10 | Manufacturing (CMC) | Approved | June 4, 1985 | Standard |
| Supplement | 11 | Manufacturing (CMC) | Approved | May 17, 1985 | Standard |
| Supplement | 14 | Manufacturing (CMC) | Approved | April 3, 1985 | Standard |
| Supplement | 13 | Labeling | Approved | January 26, 1985 | — |
| Supplement | 12 | Manufacturing (CMC) | Approved | January 26, 1985 | Standard |
| Supplement | 9 | Labeling | Approved | April 20, 1982 | — |
| Supplement | 6 | Manufacturing (CMC) | Approved | November 6, 1981 | Standard |
| Supplement | 7 | Manufacturing (CMC) | Approved | September 28, 1981 | Standard |
| Supplement | 8 | Manufacturing (CMC) | Approved | September 24, 1981 | Standard |
| Supplement | 5 | Manufacturing (CMC) | Approved | July 16, 1980 | Standard |
| Supplement | 4 | Labeling | Approved | July 16, 1980 | — |
| Supplement | 3 | Manufacturing (CMC) | Approved | February 15, 1980 | Standard |
| Supplement | 2 | Labeling | Approved | September 25, 1979 | — |
| Supplement | 1 | Manufacturing (CMC) | Approved | September 24, 1979 | Standard |
| Original application | 1 | Type 5 - New Formulation or New Manufacturer | Approved | August 6, 1979 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20230830). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Ringer’s Irrigation USP is indicated for all general irrigation, washing and rinsing purposes which permit use of a sterile, nonpyrogenic electrolyte solution.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION The dose is dependent upon the capacity or surface area of the structure to be irrigated and the nature of the procedure. When used as a vehicle for other drugs, the manufacturer’s recommendations should be followed. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permits. See PRECAUTIONS .
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS NOT FOR INJECTION BY USUAL PARENTERAL ROUTES. An electrolyte solution should not be used for irrigation during electrosurgical procedures.
Warnings
openFDA Drug LabelingWARNINGS FOR IRRIGATION ONLY. NOT FOR INJECTION. Irrigating fluids have been demonstrated to enter the systemic circulation in relatively large volumes; thus this irrigation must be regarded as a systemic drug. Absorption of large amounts can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of administered parenteral solutions. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of such solutions. Do not warm above 150°F (66°C). After opening container, its contents should be used promptly to minimize the possibility of bacterial growth or pyrogen formation. Discard unused portion of irrigating solution since it contains no preservatives.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS Possible adverse effects arising from the irrigation of body cavities, tissues, or indwelling catheters and tubes are usually avoidable when proper procedures are followed. Displaced catheters or drainage tubes can lead to irrigation or infiltration of unintended structures or cavities. Excessive volume or pressure during irrigation of closed cavities may cause undue distention or disruption of tissues. Accidental contamination from careless technique may transmit infection. Should any adverse reaction occur, discontinue the irrigant, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
Drug Interactions
openFDA Drug LabelingDrug Interactions Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.
Description
openFDA Drug LabelingDESCRIPTION Ringer’s Irrigation USP is a sterile, nonpyrogenic, solution of electrolytes in water for injection intended only for sterile irrigation, washing and rinsing purposes. Each 100 mL contains: Sodium Chloride USP 0.86 g; Potassium Chloride USP 0.03 g Calcium Chloride Dihydrate USP 0.033 g; Water for Injection USP qs pH: 5.8 (5.0-7.5). The solution is isotonic (310 mOsmol/liter, calc.) and has the following electrolyte content (mEq/liter): Na + 147; K + 4 Ca ++ 4.5; Cl − 156 The solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only for use as a single-dose or short procedure irrigation. When smaller volumes are required the unused portion should be discarded. Ringer’s Irrigation USP may be classified as a sterile irrigant, wash, rinse and pharmaceutical vehicle. The formulas of the active ingredients are: Ingredients Molecular Formula Molecular Weight Sodium Chloride USP NaCl 58.44 Potassium Chloride USP KCl 74.55 Calcium Chloride Dihydrate USP CaCl 2 •2H 2 O 147.01 The plastic container is a copolymer of ethylene and propylene formulated and developed for parenteral drugs. The copolymer contains no plasticizers and exhibits virtually no leachability. The plastic container is also virtually impermeable to vapor transmission and therefore, requires no overwrap to maintain the proper drug concentration. The safety of the plastic container has been confirmed by biological evaluation procedures. The material passes Class Vl testing as specified in the U.S. Pharmacopeia for Biological Tests — Plastic Containers. These tests have shown that the container is nontoxic and biologically inert. Not made with natural rubber latex, PVC or DEHP.
Overdosage
openFDA Drug LabelingOVERDOSAGE In the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. See WARNINGS , PRECAUTIONS , and ADVERSE REACTIONS .
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Ringer’s Irrigation USP is supplied sterile and nonpyrogenic in PICTM (Plastic Irrigation Containers). The 1000 mL containers are packaged 16 per case. NDC Cat. No. Size Ringer’s Irrigation USP 0264-2202-00 R5310-01 1000 mL Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.] However, brief exposure up to 40°C does not adversely affect the product. Do not warm above 150°F (66°C).
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: SODIUM CHLORIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 0264-2202-00 | 0264-2202 | B. Braun Medical Inc. | 16 CONTAINER in 1 CASE (0264-2202-00) / 1000 mL in 1 CONTAINER | August 6, 1979 |
| 0338-0104-04 | 0338-0104 | Baxter Healthcare Corporation | 12 BOTTLE, PLASTIC in 1 CARTON (0338-0104-04) / 1000 mL in 1 BOTTLE, PLASTIC | February 19, 1982 |
| 0264-2202 | 0264-2202 | B. Braun Medical Inc. | — | August 6, 1979 |
| 0338-0104 | 0338-0104 | Baxter Healthcare Corporation | — | February 19, 1982 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.